SCHEMBL29366016

SCHEMBL29366016

COCCN(CCc1ccc(Br)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
LTB4R Q15722 1/20 0.38
LTB4R2 Q9NPC1 1/20 0.38
HDAC1 Q13547 3/20 0.37
HDAC6 Q9UBN7 2/20 0.37
SSTR4 P31391 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
POLB P06746 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC2 Q92769 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
CHI3L1 P36222 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412345 0.88 L3MBTL1 (0.40) KDM4EGLAL3MBTL1TAAR1LTB4R
SCHEMBL13166745 0.88 HDAC1 (0.45) KDM4EGLAL3MBTL1HDAC1HDAC6
SCHEMBL6787392 0.84 SSTR4 (0.42) TAAR1LTB4RLTB4R2HDAC1SSTR4
SCHEMBL2531765 0.84 SSTR4 (0.39) L3MBTL1HDAC1HDAC6SSTR4HDAC3
SCHEMBL6743966 0.82 PPARG (0.44) TAAR1HDAC1HDAC3HDAC2NCOR2
SCHEMBL22804425 0.82 TAAR1 (0.46) KDM4EGLAL3MBTL1TAAR1LTB4R
SCHEMBL4717431 0.81 LTB4R (0.36) TAAR1LTB4RLTB4R2HDAC1SSTR4
SCHEMBL13708399 0.81 HDAC1 (0.52) L3MBTL1HDAC1HDAC6SSTR4HDAC3
SCHEMBL31618009 0.80 ADRB3 (0.40) L3MBTL1TAAR1LTB4RLTB4R2HDAC1
SCHEMBL1129151 0.79 TAAR1 (0.50) KDM4ETAAR1LTB4RLTB4R2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479849-B2 EGFR inhibitors for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-11-25 US disclosed
CN-113993872-B EGFR inhibitors for the treatment of cancer 豪夫迈·罗氏有限公司 2024-09-24 CN disclosed
US-20230054473-A1 EGFR INHIBITORS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2023-02-23 US disclosed
EP-3986896-A1 EGFR INHIBITORS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2022-04-27 EP disclosed
CN-113993872-A EGFR inhibitors for the treatment of cancer 豪夫迈·罗氏有限公司 2022-01-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054473-A1 EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, ERBB2, ERBB3 KDM4E 2939/4885GLA 3411/4885L3MBTL1 2578/4885
US-12479849-B2 EGFR inhibitors for the treatment of cancer EGFR, ERBB2, ERBB3 KDM4E 2924/4885GLA 3886/4885L3MBTL1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.